Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT03127761Recruiting
Transplant study for Medicare patients with advanced myeloma
This study looks at outcomes of an allogeneic transplant (a donor-based transplant) in people with stage II–III multiple myeloma or primary plasma cell leukemia who have Medicare. It may help doctors better understand which patients benefit and what to expect before and after transplant.
Minneapolis, MinnesotaAges Any age - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03128996RecruitingPhase 1/Phase 2
Bone marrow transplant with lighter chemo for non-cancer illnesses
This early-phase study tests a safer “lighter” conditioning chemo plan before a bone marrow transplant for people with non-cancer blood and immune disorders. It aims to reduce transplant risk while using donor marrow that does not match perfectly in the HLA type.
New Haven, ConnecticutAges 1 day–21 years - NCT03131531Recruiting
Lymphoid cancer registry for lymphoma and myeloma patients
This study is a cancer registry that collects information from people with lymphoma, Hodgkin disease, or myeloma. It helps researchers understand these cancers better by using real-world patient data.
BergamoAges 18 years+ - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT03161223RecruitingPhase 1/Phase 2
Durvalumab plus other medicines for peripheral T-cell lymphoma
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
Charlottesville, VirginiaAges 18 years+ - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia or MDS
This trial tests a special type of cord blood transplant using lab-grown stem cells to help the new blood-forming cells “take” sooner. It’s for people with severe aplastic anemia or certain MDS cases who have not responded well to standard immune-suppressing treatments.
Bethesda, MarylandAges 4–75 - NCT03188874Recruiting
Registry study for adults with AML and collected samples
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT03190928Recruiting
Study of lymphoma changes over time in follicular lymphoma
This study looks at how follicular lymphoma cells change (“clonal evolution”) over time. It may help doctors understand disease behavior and guide better future treatments, especially when people may need treatment soon.
Bethesda, MarylandAges 18 years+ - NCT03193892Recruiting
National registry for women with lymphangioleiomyomatosis
This trial is a national health registry that collects medical information from women with lymphangioleiomyomatosis (LAM), a rare lung condition. It helps researchers better understand who has LAM and what their health looks like over time.
Beijing, Beijing MunicipalityAges Any age - NCT03199066Recruiting
Study of non-Hodgkin lymphoma patients in the Czech Republic
This is an observational study that collects real-world information from people diagnosed with non-Hodgkin lymphoma. It does not test a new drug, but it may help doctors understand patient outcomes and care patterns.
PragueAges 18 years+ - NCT03197259Recruiting
Chronic lymphocytic leukemia registry study for adults
This study collects information from people with chronic lymphocytic leukemia (CLL) to better understand the disease over time. If you join, you would share your medical and health details and give consent to be included in the registry.
IzmirAges 18 years+ - NCT03207854Recruiting
Donate blood and immune samples for cancer, blood, or healthy volunteers study
This study collects blood and immune-related samples from people with cancer, certain immune-related blood conditions, or healthy volunteers. It helps researchers understand immune changes and may support future diagnosis or treatments.
Los Angeles, CaliforniaAges 19 years+ - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT03214354RecruitingPhase 2
Stem cell transplant for children with sickle cell and ABO mismatch
This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.
Calgary, AlbertaAges 1–19 - NCT03217656Recruiting
Jiaxing birth follow-up study for pregnant families
This study enrolls pregnant women in the Jiaxing area and follows them during pregnancy and after delivery to learn about mothers and babies. If you plan to stay involved through birth and follow-up, this may help researchers understand pregnancy and early childhood outcomes.
Hangzhou, ZhejiangAges Any age - NCT03243019RecruitingPhase 2
Rapamycin for lymphatic malformations in children
This trial studies whether rapamycin can reduce problems caused by cervico-facial or chest (mediastinal) lymphatic malformations in children. It may help with pain and swallowing or breathing difficulties when standard “curative” treatment isn’t possible.
LilleAges Up to 18 years - NCT03248310Recruiting
Surgery vs non-surgical care for lymphedema quality of life
This study compares how people feel day to day (quality of life) after either surgery or non-surgical care for lymphedema. It may help doctors understand which approach improves comfort, function, and overall well-being.
Harrison, New YorkAges 18–80 - NCT03255928Recruiting
Study blood clot cell activity in people with a heart pump
This study looks at how your blood’s clot-forming cells (platelets) behave when you have a heart pump device placed (short-term or long-term). The results may help doctors better understand complications and how to manage them after implantation.
Milan, MIAges 18–75 - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03280394Recruiting
Liquid blood test for mature B-cell tumors
This study looks at how a “liquid biopsy,” a test done on blood, may help in people with mature B-cell tumors. It mainly checks whether you can take part and complete the planned study procedures.
Bellinzona, Canton TicinoAges 18 years+ - NCT03295227RecruitingPhase 1
Pembrolizumab for thymus cancer that cannot be removed
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
Houston, TexasAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.